#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Journals / Geriatrics and Gerontology / 2023 - 3

Anticoagulant treatment in patients with atrial fibrillation and chronic kidney disease – a common problem in the elderly

Česká verzia

Authors: Veselý Jiří 1,2;  Pudil Radek 1,3
Authors place of work: Lékařská fakulta Univerzity Hradec Králové, Hradec Králové 1;  Kardiologická ambulance EDUMED, Náchod 2;  1. interní kardioangiologická klinika FN Hradec Králové 3
Published in the journal: Geriatrie a Gerontologie 2023, 12, č. 3: 127-134
Category: Review Article

Summary

Veselý J, Pudil R. Anticoagulant treatment in patients with atrial fibrillation and chronic kidney disease – a common problem in the elderly.


Atrial fibrillation and chronic kidney disease are strongly interacting diseases common in elderly. This combination significantly increases morbidity and mortality especially due to their impact on stroke risk. Novel (direct) oral anticoagulants (NOACs/DOACs) are generally recommended as first line therapy for stroke prevention in atrial fibrillation. There is also evidence of effectiveness in patients with mild or moderate reduction of renal function. However, the use of this treatment in patients with seriously reduced renal function is still controversial. This article provides an overview of current options and evidence guiding the clinical use of warfarin and NOACs in patients with atrial fibrillation and chronic kidney disease

Keywords:

novel oral anticoagulants – elderly patients – atrial fibrillation – chronic kidney disease – anticoagulation therapy – creatinine clerance

Zdroje
  1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370–2375.
  2. Zulkifly H, Lip GYH, Lane DA. Epidemiology of atrial fibrillation. Int J Clin Pract 2018; 72(3): e13070. 
  3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983–988.
  4. Aronow WS, Ahn C, Gutstein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. J Am Geriatr Soc 1996; 44: 521–523. 
  5. Aronow WS, Ahn C, Gutstein H. Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a long-term health care facility. J Gerontol A Biol Sci Med Sci 2002; 57: M45–46.
  6. Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death. The Framingham Study. Circulation 1998; 98: 946–952.
  7. National Kidney Foundation. NKF KDOQI Guidelines. Chronic Kidney Disease: Evaluation, Classification, and Stratification, 2002. 
  8. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3(1).
  9. Švarcová T, Veselý J. Antikoagulační léčba u pacientů s chronickým onemocněním ledvin. Cor Vasa 2019; 61: e599–e605.
  10. Mallappallil M, Friedman EA, Delano BG, et al. Chronic kidney disease in the elderly: evaluation and management. Clin Pract (Lond) 2014; 11(5): 525–535. 
  11. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population. Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1–12.
  12. U.S. Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD, USA: 2013. www.usrds.org/adr.aspx. 
  13. Bansal N, Xie D, Tao K, et al. Atrial fibrillation and risk of ESRD in adults with CKD. Clin J Am Soc Nephrol 2016; 11: 1189–1196. 
  14. Banerjee A, Fauchier L, Vourch P, et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol 2013; 61: 2079–2087. 
  15. Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363–1369. 
  16. Hart RG, Pearce LA, Aguilar MI. Metaanalysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–867. 
  17. Szummer K, Gasparini A, Eliasson S, et al. Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J Am Heart Assoc. 2017; (3): e004925. 
  18. Yang F, Hellyer JA, Than C, et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart 2017; 103(11): 818–826. 
  19. Tan J, Liu S, Segal JB, et al. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. BMC Nephrol 2016; 17: 157. 
  20. Turakhia MP, Blankestijn PJ, Carrero JJ, et al. Chronic kidney disease and arrhythmias: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J 2018; 39: 2314–2325.
  21. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation 2019; JACC.
  22. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021; 23: 1612–1676. 
  23. Connoly SJ, Ezekowitz MD, Yusuf S, et al.; the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.
  24. Healey JS, Eikelboom J, Wallentin L, et al. Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RE-LY study. J Am Coll Cardiol 2010; 55: A4.E37.
  25. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891. 
  26. Fox KA, Piccini JP, Wojdyla D. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387–2394. 
  27. Connoly SJ, Eikelboom J, Campbell J, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817. 
  28. Hohnloser SH, Hijazi Z, Thomas L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821–2830. 
  29. Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–2104. 
  30. Bohula EA, Giugliano RP, Ruff CHT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation 2016; 134: 24–36. 
  31. Harel Z, Scholzberg M, Shah PS, et al. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol 2014; 25: 431–442. 
  32. Sardar P, Chatterjee S, Herzog E, et al. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. Can J Cardiol 2014; 30: 888–897. 
  33. Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020; 42: 373–498.
  34. Stanifer JW, Pokorney SD, Chertow GM, et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation 2020; 141: 1384–1392. 
  35. Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018; 138: 1519–1529. 
Štítky
Geriatrics General practitioner for adults Orthopaedic prosthetics
Článek Editorial
Článek Preoperative examination of the elderly in primary care. Joint recommended practice of the Society of General Medicine and the Czech Gerontological and Geriatric Society ČLS JEP
Článek Recommended tools for medication review and prescription optimization in geriatric patients
Článek The day after: Atrial fibrillation and COVID-19
Článek Transthyretin amyloidosis of the heart – a diagnosis to keep in mind even in old age
Článek Should the doctor give in to the family’s insistence and give false information? (case study from practice)
Článek 28th National Gerontological Congress in Hradec Králové Fragile geriatric patient across disciplines – focus on surgery and oncology (pre- and post-operative care)
Článok vyšiel v časopise

Geriatrics and Gerontology

Číslo 3
2023 Číslo 3
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#